One target, two evidence streams: Rituximab versus ocrelizumab in relapsing multiple sclerosis: A design-stratified systematic review, meta-analysis, and concordance assessment.
PURPOSE Rituximab is widely used off-label as a lower-cost alternative to ocrelizumab for relapsing multiple sclerosis (MS), but comparative effectiveness and safety remain uncertain. We assessed direct head-to-head evidence and concordance between randomized and real-world findings. METHODS PubMed/MEDLINE, Cochrane...